Abstract
The peripheral neuropathies that develop after hematopoietic stem cell transplantation (HSCT) are very heterogeneous.1 Immune-mediated motor polyneuropathies including Guillain–Barre syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are rare but serious complications of HSCT, because they are characterized by potentially life-threatening motor deficits.1 Although both GBS and CIDP share many features, including flaccid paralysis, elevated CSF protein levels and electromyographic findings, they are considered separate clinical entities.2 Clinically, CIDP is distinguished from GBS by its course, which consists of a gradual progression over more than 2 months.2 Since the relevant literature has been almost exclusively limited to case reports, the clinical characteristics of GBS and CIDP after HSCT have yet to be elucidated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
